Is Ketamine Troche Therapy Covered by Insurance?

The Short Answer: Usually Not

For most patients, compounded ketamine troches are not covered by insurance. This applies to the majority of commercial insurance plans, Medicare, and most Medicaid programs.

This is a significant financial reality — and it's worth understanding precisely why, so you know what to do about it. Our full cost and insurance guide covers strategies for making treatment more affordable.

Why Insurance Doesn't Cover Compounded Ketamine Troches

There are three primary reasons for denial:

1. Compounded Medications Are Not FDA-Approved

Insurance formularies are built around FDA-approved drug products. Compounded ketamine troches are not FDA-approved — they are prepared by compounding pharmacies under Section 503A of the FDCA for individual patients. Most insurers classify non-FDA-approved drugs as "experimental" or "investigational," which are standard coverage exclusion categories.

2. Off-Label Use for Psychiatric or Pain Indications

Ketamine is FDA-approved as an anesthetic — not for depression, anxiety, PTSD, or chronic pain. When used sublingually for psychiatric or pain management purposes, it is off-label prescribing. Insurers often limit coverage for off-label uses, particularly for expensive or controlled substances.

3. No Billing Code for Compounded Ketamine Troches

Pharmaceutical insurance coverage is built around NDC (National Drug Code) numbers assigned to FDA-approved products. Compounded troches have no NDC number. Without an NDC, the pharmacy benefit manager (PBM) has no mechanism to process coverage — even if the insurer theoretically wanted to cover it.

What May Be Covered: The Exceptions

Provider Visit Fees

Your prescribing provider's appointment fees may be separately covered by your medical insurance, even though the medication itself is not.

A psychiatrist billing for a standard psychiatric evaluation (CPT code 90791) or medication management visit (90833 with evaluation codes) is providing a covered medical service — the fact that they're prescribing compounded ketamine doesn't change the billing for the visit itself.

Check with your insurer about whether mental health office visits are covered under your plan, and whether telehealth visits are included.

Spravato (Esketamine) for Qualifying Patients

If your diagnosis includes treatment-resistant depression (TRD) or MDD with suicidal ideation, you may qualify for FDA-approved esketamine (Spravato). Spravato has a formal FDA approval, established billing codes, and is covered by some commercial and government insurers for qualifying patients.

If cost is a significant factor and your diagnosis aligns with Spravato's approvals, exploring insurance coverage for Spravato is worthwhile before committing to out-of-pocket troche therapy.

IV Ketamine: Rare but Possible

A small number of commercial insurers have covered IV ketamine infusions for TRD patients with extensive documented prior treatment failures, particularly when the infusions are administered in a physician's office or clinic setting. This is uncommon but not impossible — particularly with strong medical necessity documentation.

FSA and HSA: Your Most Reliable Cost Reduction

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) allow you to use pre-tax dollars for eligible medical expenses. This is the most accessible and reliable way to reduce the out-of-pocket cost of ketamine troche therapy.

What Qualifies as an Eligible Expense

• Prescription medication cost (the troches): Eligible if prescribed by a licensed healthcare provider for a medical condition
• Prescribing provider fees: Medical office visits and telehealth consultations
• Blood pressure monitor: Eligible as medical equipment for home monitoring
• Home therapy supplies (with medical necessity documentation): Less certain — check with your FSA/HSA administrator

How Much This Saves

If you spend $4,800 per year on ketamine therapy (a middle estimate) and you're in the 24% federal tax bracket:

• $4,800 × 24% = $1,152 in annual tax savings

At the 32% bracket:

• $4,800 × 32% = $1,536 in annual tax savings

For most patients, HSA/FSA use meaningfully reduces the effective cost of treatment.

Practical Steps

1. Confirm that your ketamine prescription meets your FSA/HSA administrator's requirements for prescription medication expenses (it should)
2. Pay using your HSA/FSA debit card directly if possible
3. Keep all receipts, prescription labels, and provider invoices for documentation if audited
4. For FSA accounts, be aware of use-it-or-lose-it annual deadlines

How to Appeal an Insurance Denial

If your insurance denies a claim for ketamine-related services (including provider visits or a Spravato claim if that applies):

Step 1: Request the Denial in Writing

Ask for a written explanation of denial with the specific policy or code basis for the decision.

Step 2: Obtain a Letter of Medical Necessity

Ask your prescriber to write a detailed letter documenting:

• Your specific diagnosis (e.g., Treatment-Resistant Major Depressive Disorder, F33.2)
• The number and nature of prior treatment failures (e.g., "Patient has failed adequate trials of fluoxetine, sertraline, bupropion, venlafaxine, and augmentation with aripiprazole over 7 years")
• The clinical rationale for ketamine treatment
• Any peer-reviewed evidence supporting the treatment for the indication

Step 3: File a Formal Appeal

Submit the letter of medical necessity along with a formal appeal citing:

• The diagnosis
• Prior treatment failures
• Published clinical evidence for ketamine in your condition
• The specific insurer's criteria for exception or coverage of experimental treatments

Step 4: Request External Review

If the internal appeal is denied, you have the right (under the ACA) to request an independent external review of the denial. An external reviewer independent of the insurer assesses whether the denial was appropriate.

Step 5: State Insurance Commissioner Complaint

If you believe the denial was improper, file a complaint with your state's insurance commissioner. State insurance agencies sometimes intercede in cases of improper denials.

Realistic expectation: Appeals for compounded ketamine troches have low success rates. But appeals for provider fees and, if applicable, Spravato are more likely to succeed.

Employer-Sponsored Plans: Special Cases

Some self-insured employer plans (large employers who self-fund their benefits rather than purchasing commercial insurance) have more flexibility to cover non-standard treatments. If you have an employer-sponsored plan, ask your HR department or benefits administrator directly:

• Is compounded medication ever covered under our plan?
• Are there exceptions for documented treatment-resistant conditions?
• Is there a medical necessity exception process?

You might be surprised — some large employers have progressive mental health benefits.

Key Takeaways

• Compounded ketamine troches are rarely covered by commercial or government insurance due to their non-FDA-approved, off-label status.
• Provider visit fees may be separately covered — check your mental health benefits.
• FSA and HSA accounts reduce effective cost by your marginal tax rate — use them.
• Spravato (FDA-approved esketamine) is the option with insurance coverage potential for qualifying diagnoses.
• Appeals are possible but have low success rates for compounded medications; worth attempting with strong medical necessity documentation.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• Healthcare.gov: Understanding Costs — Federal marketplace resource explaining insurance terminology and out-of-pocket healthcare costs